Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Gwen M H E DackusKatarzyna JóźwiakGabe S SonkeElsken van der WallPaul J van Diest Sabine Siesling Michael Hauptmann Sabine C Linn

Published in: Journal of the National Cancer Institute (2022)

These results suggest that the best adjuvant endocrine treatment for chemotherapy-treated, ER+ breast cancer patients diagnosed aged 45-50 years consists of mainly AI followed by a switch strategy and mainly tamoxifen.

Keyphrases

estrogen receptor
breast cancer cells
early stage
locally advanced
positive breast cancer
postmenopausal women
artificial intelligence
squamous cell carcinoma
radiation therapy